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Abstract 
Background: In the Greater Mekong Subregion, adults are at highest risk for malaria, particularly those who visit 
forests. The absence of effective vector control strategies and limited periods of exposure during forest visits suggest 
that chemoprophylaxis could be an appropriate strategy to protect forest goers against malaria.
Methods: Alongside a clinical trial of anti‑malarial chemoprophylaxis in northern Cambodia, qualitative research was 
conducted, including in‑depth interviews and observation, to explore the acceptability of malaria prophylaxis for for‑
est goers, the implementation opportunities, and challenges of this strategy.
Results: Prophylaxis with artemether–lumefantrine for forest goers was found to be acceptable under trial condi‑
tions. Three factors played a major role: the community’s awareness and perception of the effectiveness of prophy‑
laxis, their trust in the provider, and malaria as a local health concern. The findings highlight how uptake and adher‑
ence to prophylaxis are influenced by the perceived balance between benefits and burden of anti‑malarials which are 
modulated by the seasonality of forest visits and its influence on malaria risk.
Conclusions: The implementation of anti‑malarial prophylaxis needs to consider how the preventive medication can 
be incorporated into existing vector‑control measures, malaria testing and treatment services. The next step in the roll 
out of anti‑malarial prophylaxis for forest visitors will require support from local health workers.
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Background
Over the past 20  years, the Greater Mekong Subregion 
(GMS) has recorded a substantial reduction in malaria 
incidence and related mortality [1]. Progress has been 
made through the successful implementation of vari-
ous disease prevention and control measures, including 
increasing coverage of appropriate vector control, early 
case detection and access to effective anti-malarial treat-
ments [2]. However, malaria remains a serious threat 
to public health, with residual transmission continuing 
in forested areas and along international borders [3–5], 
where forest goers and mobile populations are at an 
increased risk [6, 7]. The emergence and spread of resist-
ance to first-line anti-malarials, including artemisinin-
based combination therapy (ACT), in the GMS has 
revitalized elimination efforts in the region.
Forested zones are an important setting for continued 
malaria transmission with shade, humidity, protected 
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The effectiveness of key vector control measures, such as 
insecticide-treated mosquito nets (ITNs), coils and other 
repellents or barriers (including long-sleeved clothes) is 
limited in forest settings; vectors are diurnal, bite out-
doors, and workers are often engaged in hard physi-
cal labour at all hours [8–10]. Given these challenges, 
researchers have suggested that malaria prophylaxis for 
forest goers might have a potential role in prevention, 
control and elimination efforts [9–11].
Anti-malarials have been used prophylactically in a 
variety of epidemiological settings and for several at-
risk groups. Intermittent preventive treatment (IPT) 
has been implemented and evaluated in endemic areas 
for pregnant women, infants and children [12–14]. Sea-
sonal malaria chemoprevention (SMC) has been used in 
contexts where transmission is seasonal [15]. Mass drug 
administration (MDA) has a long history and recently 
has been evaluated in low transmission areas to accel-
erate elimination [16–18]. Chemoprophylaxis has been 
recommended for travellers and military personnel 
spending time in areas where transmission is likely [19, 
20]. To date, malaria prophylaxis has not been widely 
used by adult at-risk groups living in endemic areas, such 
as forest goers.
The impact of anti-malarial chemoprophylaxis among 
forest goers on the burden of malaria is contingent on 
more than just its efficacy under clinical trial conditions. 
For all health interventions, uptake is strongly affected by 
their acceptability among end users. This is particularly 
the case for preventive interventions, such as malaria 
prophylaxis, for which the benefit of participation is 
often less immediately apparent than for treatments 
[21–23]. Questions also remain about how to implement 
prophylaxis as part of a malaria control programme. A 
clinical trial in northern Cambodia has recently investi-
gated such an approach using artemether–lumefantrine 
(AL) [24]. The trial provided an opportunity to examine 
the acceptability of prophylaxis among forest goers and 
to investigate the feasibility of its implementation. Draw-
ing on qualitative research methods (in-depth interviews 
and observation), this article explores the acceptability 
of malaria prophylaxis with AL for forest goers and the 
implementation opportunities and challenges of this 
strategy. The aim is to develop recommendations for 
future implementation as part of malaria control pro-
grammes across the GMS. To this end, forest-going 
practice, forest goers’ perceived malaria risk, malaria 
prevention and treatment-related practices (includ-
ing prophylaxis), aspects of trial implementation that 
influence the uptake of forest-goer malaria prophylaxis, 
potential challenges and opportunities for integrating 




The study was conducted in Siem Pang District in 
Stung Treng Province, north-eastern Cambodia, a dis-
trict which borders with Lao PDR to its north and west 
(Fig. 1) [25, 26]. The province is bisected by the Mekong 
River and is predominantly rural. The Sekong River flows 
through Siem Pang District; there are large forests to the 
north and road access to villages is restricted during the 
rainy season. Siem Pang has a diverse population that 
includes Laotian and Kavet groups. Farming is the main 
source of income (Fig.  2). The estimated population in 
Siem Pang is 24,858 with an average annual income of 
800–1000 USD per person. There are two health centres 
in the district: Siem Pang Health Centre and Sre Sambo 
Health Centre. With 2151 malaria cases reported in 2019, 
Siem Pang district had among the highest incidence in 
the country (Data from Stung Treng Provincial Health 
Department on Malaria situation in Siem Pang, Stueng 
Treng, as of February 2020). 
In Cambodia, malaria cases are caused by Plasmodium 
falciparum, Plasmodium vivax, or a mixed infection, 
with P. falciparum being predominant among confirmed 
malaria cases until 2011 [27]. Plasmodium vivax has 
not experienced the same decline and is now the domi-
nant species, accounting for 85% of the malaria cases 
in 2019. Evidence to date also suggests that low density 
and asymptomatic infections are an important source of 
malaria transmission in the region [28]. Anopheles mini-
mus and Anopheles dirus are important mosquito vectors 
of malaria in Cambodia particularly in forest and forest 
fringe areas in hilly or mountainous areas, cultivated for-
ests, and rubber plantations [27] and along international 
borders. In 2014, 58% of the population, or approximately 
8.6 million people, were estimated to live in malaria risk 
areas, where transmission occurs primarily in the hot and 
rainy season between July and November [29]. Impor-
tant elimination interventions used across endemic 
areas include testing and treatment by village malaria 
workers, use of LLINs and targeting at-risk populations 
with 10,422 forest packs, including LLINs and LLIHNs, 
reported to be distributed to forest goers in 2019 [27].
The study was part of the clinical trial evaluating the 
efficacy of anti-malarials for prophylaxis (ClinicalTri-
als.gov Identifier: NCT04041973 [24]), based at the 
Siem Pang Health Centre. This trial randomized for-
est goers without clinical malaria at baseline to either 
artemether–lumefantrine (AL, brand name Coartem®) 
or a multivitamin. AL is the most widely used first-
line anti-malarial treatment worldwide and is very well 
tolerated with an excellent toxicity profile. In Cambo-
dia, AL has shown high efficacy [27], but it is not used 
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routinely for for treatment. It must be taken with fat to 
maximise absorption of lumefantrine. The regimen was 
begun with a full 3-day course followed by two doses 
once weekly continuously for one, two or three months 
depending on how long they continued to return to the 
forest. The clinical trial took place from February 2020 
to April 2021 [30]. Data collection for the qualitative 
study was conducted throughout the trial.
Respondents
In-depth interviews (IDIs) were conducted with trial par-
ticipants who reported visiting forested areas on more 
than 14  days/year. During follow-up visits for the trial, 
potential respondents were approached by members of 
a community engagement team attached to the clinical 
trial to enrol them in this study. Consenting participants 
were asked about forest-related activities and prophy-
laxis. Interviews were also conducted with forest goers 
Fig. 1 Map of study district
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aged 16  years or above who were not recruited in the 
trial due to trial ineligibility: individuals with planned 
pregnancy, history of allergy to anti-malarials, or cardiac 
conduction problems. This was done to see if their views 
differed from those with direct experience of prophylaxis. 
Recruitment took place in villages and the health centre 
in Siem Pang. Additional in-depth interviews were con-
ducted with local healthcare workers, community lead-
ers, policymakers, and the trial staff in the village, at their 
place of work, or via an online video/audio call (when 
COVID-19 control measures prevented face to face 
interviews).
The study was approved by the Oxford Tropical 
Research Ethics Committee (534-19) and Cambodian 
National Ethics Committee on Health Research (008). All 
respondents provided informed consent to participate 
in the study and for the interviews to be audio-recorded. 
Written informed consent was obtained from all study 
participants when they were recruited in their villages 
or at Siem Pang Health Centre, and verbally confirmed 
before the interviews were conducted several weeks later 
during the trial follow-up period. For other stakeholders, 
written informed consent was obtained before the inter-
views at their places of work.
Local community members and authorities were 
engaged from an early stage of the trial. Before begin-
ning data collection, a large orientation meeting, smaller 
community meetings, and meetings with groups of forest 
goers were held to explain about the trial activities and 
their purpose. There was regular contact and communi-
cation between the study team, local health workers, as 
well as commune, district, and provincial level leaders.
Data collection
Data collection tools and in-depth interview guides for 
each type of respondent were developed based on the ini-
tial topics drawn from a recent qualitative study on for-
est going and malaria-related risk in Cambodia [9]. The 
questions on acceptability of prophylaxis were designed 
based on a theoretical framework on acceptability of 
health interventions comprising: affective attitude, bur-
den, ethicality, intervention coherence, opportunity 
costs, perceived effectiveness, and self-efficacy (Table 1) 
[31]. Questions on the implementation of the interven-
tion were designed based on the Measurement Instru-
ment for Determinants of Innovations [32] framework to 
capture the multi-level contexts of implementation deter-
minants: socio-political context, health system context, 
health worker characteristics, and client characteristics 
[33].
Fig. 2 Livelihoods in Siem Pang A farm in the forest, B Rice fields, C 
logging
Table 1 Key definitions for each component of the theoretical framework of acceptability
Adapted from Sekhon et al. [31]
Affective attitude How an individual feels about the intervention
Burden The perceived amount of effort that is required to participate in the intervention
Ethicality The extent to which the intervention has good fit with an individual’s value system
Intervention coherence The extent to which an individual understands the intervention and how it works
Opportunity costs The extent to which benefits, profits, or values must be given up to engage in the intervention
Perceived effectiveness The extent to which the intervention is perceived as likely to achieve its purpose
Self‑efficacy An individual’s confidence that they can perform the behaviour(s) required to participate in 
the intervention
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IDI guides for each group of interviewees (see Addi-
tional files 1, 2, 3, 4, 5 and 6) were initially designed in 
English and translated by a native Khmer speaker and 
field researcher. The guides included key topic areas 
and lists of suggested questions and were designed to 
be used in a flexible and iterative manner: interview-
ers would be reactive to the responses and probe or 
ask follow-up questions to elicit the information on 
the specific topic emerging during the interviews. Dur-
ing development, the translations of the topic areas 
and suggested questions were discussed and checked 
with the team who were also trained on how to use 
the guide. The guide was then piloted with the first 
recruited study participants to check for any miscom-
munication and revised as necessary.
Interviews took place in villages, typically at par-
ticipants’ homes or communal places, or at the health 
centre. Respondents were interviewed by one of two 
trained field researchers fluent in Khmer and Lao. 
Stakeholders were interviewed by a social scientist in 
English, with live translation to Khmer by one of the 
two field researchers.
Observation
Observation data of the trial was recorded in an imple-
mentation diary in which the study team took field notes 
from observing the trial activities throughout the trial 
implementation. The study team had regular debrief 
meetings to review these notes. The field notes were 
imported and coded on NVivo for thematic analysis along 
with the interview data. The implementation diary was 
designed to record observation data about the implemen-
tation of the trial that may not have been captured from 
the interviews with trial staff and other respondents. The 
notes included details about trial activities. For example, 
questions that were raised by community members dur-
ing community meetings, and challenges that occurred 
during recruitment or follow-up activities in the villages.
Data processing and analysis
After respondents gave their consent, interviews were 
audio-recorded and subsequently transcribed and trans-
lated to English by field researchers. The translated 
transcripts and field notes were imported into NVivo 
version 12 (QSR International Australia) for qualitative 
thematic analysis. All transcripts were read several times 
and coded line-by-line using inductive and deductive 
approaches: the codebook used was initially based on the 
main research topics. Subsequently, during the process of 
coding, themes that emerged from the data were incor-
porated into the codebook.
Results
Demographic characteristics of respondents
The findings presented are based on individual in-
depth interviews with 27 forest goers including 23 trial 
participants and 4 non-trial participants. A further 19 
interviews were conducted with healthcare workers, 
community leaders, policymakers, and trial staff. Char-
acteristics of the respondents are summarized in Table 2. 
The findings were also informed by analysis of the obser-
vations during implementation of the trial carried out at 
the site and recorded as field notes by members of the 
trial team. It was found that activities and malaria-related 
Table 2 Demographic characteristics of respondents

































 Healthcare workers 7
 Community leaders 5
 Policymakers 3
 Trial staff 4
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experiences of forest goers were similar irrespective 
of whether they participated in the trial; while male 
respondents reported being more mobile and engaged in 
multiple forest activities than their female counterparts.
Forest goers and forest visits
Environment
In Siem Pang, forest-going and farming were described 
as important livelihood activities (Fig.  2) and the main 
source of income. Farms are usually located at the forest 
fringes on the edge of the forest or close to the villages. 
Rice, cassava, and cashew nuts were the main agricultural 
crops. Forest goers reported engaging in various forest 
activities including hunting, logging, fishing, and collect-
ing forest products, such as mushrooms, honey and bee’s 
nests, wild orchids, resin, and particularly malva nuts 
(Samrong). Respondents described travelling to the for-
est by foot, boat, motorcycle, or tractor (“machine cow”); 
the latter was described as crucial to transport their 
supplies to the forest and for bringing out forest/farm-
ing products on return. Forest goers are predominantly 
male and engaged in labour-intensive work in the forest. 
Respondents described visiting the forest usually with 
their male family members or friends, except when col-
lecting Samrong for which a whole family with females 
and children would often join. Apart from local residents 
who regularly visit the forest, forest rangers and military 
officials occasionally patrolled in groups with permanent 
campsites in the forested areas.
Seasonality
Collecting forest products was described as a year-round 
activity, with forest goers collecting different products in 
different seasons. Respondents mentioned visiting the 
forest on a regular basis when they have time off from 
their farm work, and especially when they combined for-
est visits with finding food in the forest: “tov rok luy, tov 
rok sad, tov rok banle” (“make money, find animal and 
vegetable”) was a common response when forest goers 
explained why they went to the forest. Respondents also 
described the harvest season as the busiest time in their 
farm during which some made fewer trips to the for-
est and usually spent nights at small farmhouses in rice 
fields or farms with their family members. Farmhouses 
were often described as a hut; some with a roof and walls 
made of tree branches and leaves and some without walls 
(Fig.  2a). After the harvest season, most respondents 
would stay in their home village, whiles some male fam-
ily members described going back to the forest or look-
ing for a temporary job, such as working in plantations, 
in Stung Treng or in nearby provinces.
Forest visits
Respondents described their resting places as make-
shift camps, the details of which depended on the size 
of the group. Forest goers commonly slept in ham-
mocks under trees or under a tent built using a rubber 
cloth or tarpaulin. The locations for setting up a sleeping 
place were often in a clear, flat area and/or by a stream 
or water source in the forest so they could use the water 
for cooking or washing. The length of forest visits usu-
ally depended on the nature of each activity in the forest, 
ranging from a few days to weeks, for example, hunting 
and tracking animals, or finding and collecting enough 
Samrong for sale. They also described other factors such 
as running out of food or getting sick in the forest. One 
respondent mentioned travelling back and forth to the 
forest to get more food from the village for the group 
members during their forest visits. Nine respondents 
mentioned logging and collecting wood to build houses 
in the village or to sell, however participants did not 
discuss the activity and its whereabouts in detail dur-
ing interviews. During follow-up visits, staff observed 
that villagers discreetly engaged in logging activities and 
avoided disclosing the locations in the forest for fear of 
being punished by the authorities.
Respondents recognized the risk of malaria from their 
forest visits: some described that the risk was anywhere 
in the forest, others specified names and descriptions of 
particular hotspots, such as mountains, streams, or areas 
with certain kinds of trees such as bamboo in the for-
est. Some respondents also associated those places with 
the presence of mosquitoes. One described past malaria 
infections as unavoidable with the limited protection 
available, for example when they were urinating in the 
forest, mosquitoe bites were unavoidable. A few respond-
ents also felt that they were at risk at their farms describ-
ing the environment as having a lot of mosquitoes, trees, 
and rubbish.
Interviewer (I): Do you think anything you do puts 
you at risk of getting malaria?
Respondent (R): Yes, at risk because we cannot pre-
vent 100%. Mosquitoes bite when we go to urinate in 
the forest. There are a lot of mosquitoes in the for-
est…Ta Ngoy mountain…if I go to this place I get 
malaria.
IDI: Male, 39  years old, trial participant from Samor 
Khnong village
Experience of malaria infection, prevention and treatment
Experience of multiple bouts of malaria
All respondents described having had malaria in the past, 
with some having had multiple bouts in a year. Most 
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respondents described mosquito bites as the main cause 
of malaria, whereas some mentioned poor hygiene or 
hot weather as additional causes. Respondents described 
malaria symptoms as headache, chills, cold, sweats, 
fatigue, feeling hot in the chest, and muscle pain. The 
cycling of fever was used to distinguish malaria from 
other febrile illnesses. Most respondents mentioned that 
they had tested positive and been provided with an anti-
malarial by a village malaria worker (VMW) in the past. 
Although asymptomatic malaria was generally not recog-
nized among forest goers, most health care workers and 
half of trial participants said it is possible to have malaria 
without symptoms from their past experience. Possible 
infection after mosquito bites but prior to symptoms was 
also recognized.
“It’s possible because after getting mosquito bites, 
patient don’t have symptoms yet, so after people 
come back from the forest they need to do RDT.”
IDI: Male, VMW from O’Chay village
I: Do you think you might have malaria but do not 
have symptoms?
R: Yes, because I don’t know I have malaria in my 
body or not. If have mosquito bite, I can get malaria.
IDI: Male, 39  years old, trial participant from Samor 
Khnong village
Use of multiple prevention measures
Forest goers reported using a combination of measures 
including long sleeved clothes, sometimes with bala-
clava or gloves, making fire, and sleeping under mos-
quito nets to prevent mosquito bites in the forest. Most 
respondents mentioned receiving an ITN from VMWs 
and/or a health centre, whereas some purchased the 
nets from a local market. A hammock and blanket were 
mentioned as an alternative for some when they did not 
bring the net to the forest. A few respondents mentioned 
using mosquito coils and fewer reported using mos-
quito repellents because of their higher price and avail-
ability in Siem Pang. Although no respondents described 
taking medicine to prevent malaria prior to the study, 
one respondent mentioned taking paracetamol that he 
bought from a local market to the forest in case he got 
sick. One respondent reported that in the past villagers 
brought antimalarial medicines for self-treatment in the 
forest when there were signs of malaria without having a 
malaria test.
Experience of malaria testing and treatment
Respondents reported being familiar with the VMWs 
and/or malaria mobile workers (MMWs) in their village 
as the primary point of malaria testing and treatment 
and whose service also included referring patients to 
the health centre (HC) in Siem Pang. A few forest goers 
reported visiting the health centre for a malaria test 
because of additional benefits e.g. check-ups for other 
illnesses, trust in the HC nurses, proximity of their 
house to the health  facility, or unavailability of VMWs 
or MMWs in the village. Some described a preference 
to visit private clinics or pharmacies because they 
provided a faster service than the HC. One respond-
ent described buying anti-malarials at a clinic during 
the weekend for self-treatment because he needed to 
return to work in the forest quickly.
Side effects of past malaria treatments were fre-
quently mentioned by forest goers. These side effects 
(e.g. fatigue, dizziness, vomiting, nausea) caused some 
to visit private clinics (for intravenous fluids) or a tra-
ditional healer. Although most did not recall or know 
the name of the antimalarial they had taken (in Siem 
Pang, antimalarial or malaria medicine is frequently 
referred to as “Thnam Krun Chanh” in Khmer or “Yaa 
Krun Chanh” in Lao), malaria workers and trial staff 
described that quinine, mefloquine, or artesunate-
mefloquine had been provided for treatment by the 
VMWs and health centre staff, or private clinics and 
pharmacies in the past.
Policymakers and malaria workers described how 
VMWs and MMWs are tasked with testing up to 50 vil-
lagers per month to detect symptomatic and asympto-
matic cases in their village as an active case detection 
strategy to eliminate P. falciparum. VMWs reported diffi-
culties persuading asymptomatic individuals to be tested. 
Even though testing services were easily available (VMW 
services are based at homes in the villages, and MMWs 
are stationed at a health post on the roadside, at an entry 
way into or out of the village, or they visit the forest or 
farms to do active case finding), the workers described 
having to go and visit villagers themselves when they 
came back from the forest to convince them to take the 
test.
Acceptability of prophylaxis
The results presented here are based on interviews with 
trial participants during follow-up visits after one or 
two months of trial drug administration, non-trial par-
ticipants at baseline, as well as with stakeholders at vari-
ous time points during the trial, and observations made 
throughout its implementation. Findings are reported 
based on the framework on acceptability of health inter-
ventions. It was found that awareness of the clinical trial, 
worries about malaria infection and its (economic) impli-
cations, and perceived effectiveness of prophylaxis con-
tributed to the acceptability of prophylaxis.
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Intervention coherence (awareness and understanding)
Trial participants appeared to be well aware of the pur-
pose of the trial, the drugs, and the activities. The par-
ticipants were informed about malaria risks and how to 
protect themselves, particularly how a person can get 
infected from mosquito bites, how the prophylaxis may 
prevent the infection, and why they should continue to 
protect themselves by using mosquito nets. Trial staff 
viewed community meetings and forest goer meetings 
prior to the recruitment as conducive to this aware-
ness and understanding of malaria (i.e. cause of infec-
tion, mosquito bites) and the aim of the trial (i.e. how 
prophylaxis can prevent or reduce the chances of get-
ting sick). Respondents discussed how some villagers 
were not informed about the trial activities in the vil-
lage, mainly because they were working in their farm 
away from the village when the meetings took place 
and thus did not participate. Four non-trial participants 
who were ineligible to join the trial because of their 
health reported that they were informed about the trial 
by VMWs or MMWs in their village, and were inter-
ested to take anti-malarials to protect themselves from 
malaria if their health conditions were better.
Ethicality (fit with values and preferences)
Trial participants joined the trial because they were 
concerned about having malaria in the forest. Of all the 
diseases, malaria worried them the most: it was seen as 
a dangerous disease; potentially deadly if left untreated. 
Some respondents described their concerns of the 
infection resulted in loss of time from work, particu-
larly those who lived in remote villages. Availability of 
regular health check-ups and compensation for travel 
cost each time participants came to a follow-up visit 
were part of their motivation to join the trial. Other 
perceived advantages from trial participation included 
the possibility of better care for another illness or acci-
dent (although this was not explicitly included in the 
trial design). For example, during enrolment, medica-
tions for some common health problems e.g. muscle 
pain, gastritis, or vitamin supplements, were offered to 
the participants who were ineligible for the trial. Blood 
pressure was checked for participants in high-risk 
groups for hypertension and those found to be hyper-
tensive were advised to go to the health centre for med-
ical advice. The staff observed that the programme’s 
provision of care was positively received by the partici-
pants, describing that they felt happy that someone was 
taking care of their health and well-being. Village chiefs 
and VMWs described being concerned about whether 
malaria cases might increase after the trial had finished.
“If I take the medicine and still feel ok, then I 
would continue to take it. If not, then I would not 
take it because it would make me feel worse.” 
IDI: Male, 28  years old, trial participants from Lakay 
village.
Affective attitude
Forest goers were positive about the trial, describing 
trust in staff and the good reputation of the research cen-
tre. Participants often referred to trial staff as “lok krou” 
or “neak krou”, and “lok krou pet” or “neak krou pet” 
(referring to male/female teacher and doctor in Khmer; 
VMWs/MMWs are often referred to as “pet phum” or 
village doctor). Interviews with the trial staff highlighted 
trust and clear communication as important factors in 
recruiting participants. This was also crucial for explain-
ing the medicine’s preventive value, how to take the tab-
lets and why it is important to take them according to the 
instructions. Interviews with, and observations by, the 
staff highlighted potential participants’ questions about 
the drug’s efficacy during the recruitment activities. 
Some respondents asked during interviews whether the 
drug can really protect and if so for how long. Interviews 
with the trial staff found that the participants would like 
to know which trial drugs (i.e. AL or multivitamins), if 
any, are effective at preventing malaria.
“The drugs are good, easy to take, no side effects ... 
I like it because they can protect me from disease. 
Someone told me that s/he stopped taking them 
because s/he had side effects, like feeling dizziness, 
feeling as if they would fall down when walking, or 
having blood in the stool.”
IDI: Male, 32 years old, trial participant from Kirvongsa 
Krom village
Burden and opportunity costs
Side effects of the antimalarial were described as the 
main determinant for respondents to make a  decision 
to join the trial or continue to take prophylaxis. Most 
respondents reported experiencing minimal side effects 
from the preventive medicine and continuing to work 
and visit the forest as usual. Some reported staying at 
home and working less during the first few days after tak-
ing the trial drugs due to side effects, such as dizziness, 
fatigue, blurred vision, nausea, and/or vomiting. The trial 
was open label so participants would have been able to 
identify which medication they were taking. Policymak-
ers and staff were also familiar with the complaints about 
side effects associated with anti-malarial treatment. One 
non-trial participant discussed how he was willing to 
Page 9 of 15Jongdeepaisal et al. Malaria Journal          (2021) 20:446  
take the preventive medicine despite having had severe 
side effects from anti-malarials.
Trial staff observed that the trial participants linked 
the severity of side effects with the number of tablets per 
dose (per day), and that those side effects were reported 
mostly during the first and second days of the AL course. 
Staff also observed more complaints about side effects 
when the participants received “the yellow one” (i.e. 
AL). Some participants preferred taking “the black one” 
(i.e. multivitamins) because there were fewer tablets per 
intake/dose. Some respondents reported that they pre-
fer to take the prophylactic once a week (taken in week 
2 onwards) rather than three days consecutively (taken 
in week 1) as they felt less comfortable taking many pills 
within a short period of time. They described their con-
cern about side effects relating to whether it would affect 
their work in the forest, farm, or around the house. Staff 
also reported that older female participants and younger 
participants complained more about the side effects than 
other groups of participants. They were reassured and 
(again) advised to take the medicine after a meal.
“Some people complained, especially females were 
scared of side effects, didn’t want to take the drug … 
a few people felt dizziness after taking the drugs … 
especially young boys they felt uncomfortable after 
taking the drugs. Villagers feared malaria medica-
tion may cause side effects such as dizziness, nausea 
and vomiting because most of them had malaria 
before and had taken drugs for malaria.”
IDI: Male, 23  years old, trial participant from Kiribas 
Leu village
In terms of the trial procedures, participants disliked 
having blood samples taken, which was viewed as harm-
ful for their bodies or general health (“losing blood”) 
and that it may cause fatigue and dizziness. Trial staff 
described participants’ concern about the amount of 
blood taken for pharmacokinetic analysis (1 ml for each 
participant) which is more than the usual dried blood 
spot for a malaria test that most villagers are familiar 
with.
Perceived effectiveness
Respondents described the effectiveness of prophylaxis 
in terms of fewer malaria cases and better health. They 
observed that they were not infected with malaria during 
the trial. One VMW reported that participants came to 
them to have a malaria test because they wanted to know 
whether the medicine can protect them from malaria. 
Male and female respondents did not perceive effective-
ness or acceptability of prophylaxis any differently. Nev-
ertheless, male community members were more mobile 
than their female counterparts and their mobility affected 
their uptake of prophylaxis (taking the tablets and/or 
joining the trial) and attending a follow-up visit. Females’ 
motivation to take prophylaxis may be influenced by 
their pregnancy and/or contraceptive use: one female 
non-trial participant described that the medicine would 
be beneficial but did not join the trial due to her future 
pregnancy plan.
Trial participants whose use of other malaria preven-
tion measures in the forest was limited were keen to con-
tinue taking prophylaxis after the trial. For example, they 
could usually only use bed or hammock nets, wear long-
sleeved clothes, and/or make fires in the forest, whereas 
mosquito coils or repellents were too costly or unavail-
able in the village. One forest goer felt that the medicine 
can protect him from malaria and continued to use a 
mosquito net because the protection is not “100%”. This 
was also highlighted during interviews with healthcare 
providers. They described the benefits of the medicine in 
preventing malaria at times when villagers are engaged in 
forest activities.
“In the explanation you have to mention concerns 
… what are the benefits for them in the future. One 
example is that some people cannot use the nets 
100%. Sometimes when the man is drunk, they may 
sleep outside of the net. If we can provide the drug to 
them, it’s also a kind of prevention … For the forest 
goers, at night time, if they are going to pass stool in 
the jungle … or when they travel and carry the nets 
on their back, during when they are not protected 
and the mosquito can bite them.”
IDI: Male, 50 years-old, healthcare worker in Siem Pang
Some respondents’ motivation to participate during the 
subsequent recruitment in later villages was affected by 
the perceived effectiveness of prophylaxis and decreased 
number of cases from the initial villages. Trial partici-
pants were also highly motivated to join the trial during 
the Samrong season (March–April) and rainy season 
(July–October) during which they travelled regularly to 
the forest or forest farm. Observations in the villages sug-
gested that they were less motivated when the forest vis-
its become less frequent during the dry season or after 
the harvest (December-February). The follow-up inter-
views with VMWs and community meetings in the village 
also suggested greater trial attrition and lower adherence 
to the trial drug at this time.
Self‑efficacy
Trial participants reported good adherence to the trial 
drugs, although some mentioned missing the occasional 
dose because they forgot or were too busy with work. 
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No-one reported discarding or sharing doses. Trial staff 
described that most participants were able to take the 
drugs as indicated and that the provided drug calendar 
was useful to remind participants to take the prophylaxis 
on time. However, participants needed clear explana-
tions, particularly in their own language/dialect in some 
villages, to ensure that they were able to understand the 
written schedule. VMWs and village chiefs described the 
provision of prophylaxis in groups—rather than individu-
ally—as a more effective approach because group mem-
bers were able to remind each other to take the drugs as 
instructed and to take the drugs with them on visits to 
the forest, which reduced the chances of missing doses. 
Trial staff also described the advantage of selecting a rep-
resentative or a group leader of forest goers to monitor 
his or her group member’s drug intake.
I: How should we explain to villagers why they 
should take medication when they’re not sick?
R: I think it will take time like I said. We also need 
to be patient and gentle when explaining to them … 
if you get sick it can get worse … working with the 
people in this district, sometimes they cannot read a 
word. What we have in our stamps [referring to the 
drug calendar], the symbols like for day and night-
time, what it means, they don’t even know what 
those mean. We need to find someone who is close 
to them to remind them all the time … if they do 
not take the medicine as prescribed it will not work, 
right? Because the medicines the doctor gives them, 
they need to take as they were told.
IDI: Female, 39  years old, community leader in Siem 
Pang.
Implementation opportunities and challenges
Interviews with trial participants and staff suggested 
that the community and participants were satisfied 
with the trial and the care they received. Respondents 
described the research team, VMWs, and health centre 
as preferred providers of prophylaxis in the future. When 
probed about this, respondents described clear explana-
tion about prophylaxis and provision of (ancillary) care. 
Familiarity with, and proximity to, VMWs were reasons 
for preference for VMWs. Trial staff reported that, with 
additional training, VMWs would be suitable provid-
ers because they are local residents who are aware of 
their neighbours’ forest visit schedule and able to com-
municate in local/ethnic languages. A few respondents 
described the health centre to be a good option as a 
trusted provider in general. For other households, how-
ever, a private clinic was the preferred health facility 
because of the faster provision of services and treatment 
of other diseases.
Trial staff described how community meetings and 
stakeholder engagement contributed to coopera-
tion of participants, particularly in the pre-recruit-
ment period, among community members who could 
spread the word to forest goers who may be working 
away from the village in a farm or the forest. Engag-
ing trusted members of the community, such as 
VWMs and/or MMWs, village chiefs, and sometimes 
the elderly was described as contributing to a wider 
provision of information in the villages. Observations 
by trial staff also found that conducting recruitment 
and follow-up visits in the village, rather than at the 
health centre, is a better approach to minimize miss-
ing potential participants and losing them to follow-
up. Female staff reported paying special attention 
when recruiting female participants who would have 
to consult with their partners on their use of contra-
ceptive pills and condoms, which were required in the 
trial protocol for females of reproductive age.
Trial staff viewed support from VMWs/MMWs in 
the village as crucial for communicating important 
messages in the local language and supporting the 
communication between the villagers and the trial 
team. In some villages where Lao is more commonly 
spoken, staff emphasized the importance of commu-
nicating with participants in their language, especially 
when explaining drug administration. In some study 
villages where languages such as Kavet were widely 
spoken and study staff were not sufficiently fluent, 
VMWs or MMWs who are local residents and trusted 
village members were asked to help. However, com-
munication with the VMWs was sometimes challeng-
ing: using mobile phones was not easy due to poor 
mobile connectivity, especially in remote villages, 
from which the staff were informed about recent 
malaria cases in one village only from the VMW 
monthly meeting at the health centre.
Interviews with policymakers highlighted concerns 
about the potential effect of prophylaxis on ITN use. 
They raised the question whether participants might 
consider the protection offered by prophylaxis as suffi-
ciently high that participants would no longer use other 
prevention measures, particularly ITNs. Policymakers 
emphasized the need for a clear and thorough explana-
tion about this approach and how prophylaxis was only 
one of several ways to protect against malaria and not a 
replacement for nets or other vector control measures. 
Trial participants reported that they still used mosquito 
nets and described that the medicine may not entirely 
protect them from malaria, or that without the net they 
could not sleep in the forest because mosquitoes still bite 
and make a noise near their ears.
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Discussion
Drawing on in-depth interviews and observations, the 
findings of this study indicate that prophylaxis with AL 
for forest-goers in northern Cambodia is acceptable under 
trial conditions. Several findings support this conclusion: 
the community’s awareness and perceived effectiveness of 
prophylaxis, their trust in the provider, and malaria as a 
local health concern. Effective implementation of prophy-
laxis depends on addressing critical concerns by forest 
goers and stakeholders related to the side effects of anti-
malarials, the influence of prophylaxis on other preven-
tion practices, dealing with complex forest-going activities 
and access to and quality of malaria-related care.
Concerns about potential side effects and their eco-
nomic implications discouraged uptake in this and previ-
ous studies. This is unsurprising given past experiences 
of anti-malarials (e.g. mefloquine, artesunate-mefloquine 
(ASMQ) [9] and has been described in regard to the 
administration of (preventive) anti-malarials in many 
contexts. For example, the perceived side effects of 
MDA in Battambang (Cambodia) led to lost productiv-
ity, particularly during the farming season, and additional 
healthcare payments (for intravenous fluids) [11, 22, 34], 
which discouraged participation. Pregnant women who 
received preventive anti-malarials (as part of IPTp) have 
also raised concerns about the unwanted effects of anti-
malarials, such as vomiting, worries that the drugs may 
affect their pregnancy or children [35, 36] and the extra 
spending on food after taking the medicine [36]. Trav-
ellers’ anti-malarial choices were also influence by pill 
burden [37, 38], cost [39, 40], perceived risk, travel char-
acteristics [38, 41, 42] and scepticism about effectiveness 
[42]. A recent systemic review highlighted how potential 
side effects influence adherence to chemoprophylaxis 
among travellers [43]. This highlights the importance 
of selecting a well-tolerated regimen for any preventive 
medication including anti-malarial chemoprophylaxis.
The trial team, comprised of medical doctors, nurses 
and health centre staff, assisted by VMWs and MMWs as 
the service providers, was well received by participants. 
The team’s track record of treating malaria patients and 
providing clear information about the trial strength-
ened the acceptability of prophylaxis [44, 45]. The find-
ings indicate that trust in the trial team was sufficient 
reason to participate even if forest goers did not have a 
complete understanding of the prophylaxis. The roles of 
inter-personal and institutional trust prompting uptake 
of preventive anti-malarials have been highlighted else-
where—both in clinical evaluations of interventions and 
as part of real-life implementation [46–50].
VMWs and MMWs were often regarded as a sen-
ior, educated, and trusted member of the villages, even 
though most of them had had no higher education. As 
described elsewhere, they were recognized as the main 
point of care for malaria testing and treatment in the 
study communities [9, 35, 51–53]. Trial staff were confi-
dent that, if provided with the necessary training, VMWs 
could provide prophylaxis to forest goers. With a system 
of monthly meetings already in place, the district health 
centre could also provide the necessary training and sup-
port to VMWs who are well-placed to communicate the 
potential side effects that participants (may) experience.
Participants were motivated to participate by concerns 
about malaria and the increased risk of malaria associ-
ated with forest visits. In some cases, the enthusiasm 
to participate was influenced by the frequency of forest 
visits, which varied over the course of a year due to the 
nature of forest activities. Some forest goers, especially 
men, were highly mobile and their time away from the 
village affected the uptake of prophylaxis (or attendance 
at follow-up visits with trial staff). Some looked for tem-
porary employment in other districts or provinces, par-
ticularly after harvest or in the dry season when forest 
visits yield fewer wild products. Forest goers may also 
engage in logging activity whose illegal nature might 
influence their decision to participate; they may not wish 
to disclose the information of their forest visits, such as 
locations or length of stay, to unfamiliar individuals or 
authorities. Forest goers engaged in a variety of differ-
ent activities; knowing the travel patterns of forest goers 
and the local community’s calendar for visiting the forest 
are important pieces of information to predict the likely 
uptake of, and adherence to, prophylaxis.
The seasonal timing of preventive therapy has been 
discussed with regard to the implementation of MDA in 
Cambodia. Mild illnesses were linked to administering 
anti-malarials in the rainy season [31, 54], when uptake 
was affected by farming obligations [55], and work-
related absences from villages [38, 56, 57]. Travel has also 
led to missed doses of IPTc, while distance and difficulty 
travelling in the rainy season created barriers for staff to 
distribute IPTc [58]. For IPTc, respondents seemed posi-
tive about home-based delivery [54, 59], whereas in some 
cases respondents expressed concerns about caregivers’ 
ability to administer drugs at home [58]. Given their resi-
dence in, and proximity to, the community, VMWs are 
aware of the timing of forest-going and hence are well 
placed to be the provider of prophylaxis to forest goers.
These findings indicate that the respondents contin-
ued to use malaria prevention measures they had been 
using before they joined the trial. This may allay some of 
the concerns policy makers expressed about prophylaxis 
competing with ITN use. This may have resulted from 
the emphasis that trial staff placed on continued ITN/
hammock net use during the engagement activities (e.g. 
community meetings) and enrolment. Furthermore, even 
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when taking prophylaxis, bites from the vectors often 
remained a nuisance. The prevention provided by anti-
malarials, has often been viewed as incomplete: the par-
ents of infants who received IPTi did not view this (even 
vaccinations) as full protection; similarly, caregivers of 
children who received IPTc, did not perceive the medica-
tion as a substitute for bed net usage [58].
The findings from this study can be summarized as 
four main implications for the intervention (see Table 3). 
Ideally any future implementation of prophylaxis for for-
est goers in real-life circumstances should be accompa-
nied by simultaneous evaluation of its impact on other 
prevention practices. Communication strategies should 
continue to frame preventive anti-malarials as part of a 
package of interventions, emphasizing the need for each 
intervention. Combining the use of anti-malarials and 
ITNs was suggested to optimize elimination strategies 
in the context of multi-drug antimalarial resistance [60]. 
A recent study also suggested that IPT for forest goers 
should be considered as a strategy given the ongoing 
low-density transmission among this group [61]. How-
ever, this would generally involve less frequent dosing 
than prophylaxis with consequent gaps in protection. To 
strengthen the use of prevention measures, prophylaxis 
could be provided as part of a set of interventions tailored 
for needs of forest goers, adding to existing local malaria 
services such as intermittent screening, distribution of 
forest packages, early diagnosis and effective treatment.
Strengths and limitations
This is the first study that has used qualitative research 
methods to specifically address acceptability and fea-
sibility of malaria prophylaxis among forest goers in 
the GMS. Using a team of three trained researchers 
to collect data guarded against the undue influence 
of a single data collector on the findings. The find-
ings are mainly drawn from reported data and might 
be subject to desirability bias, however, observations 
and informal conversations provided additional infor-
mation on the context of trial implementation and on 
sensitive topics, such as logging. The interviews were 
conducted in Khmer and Lao which are the spoken 
languages in the participants’ daily lives. Interviews 
with stakeholders were conducted in English with 
translation by a local team member when necessary; 
some were conducted via an online call due to travel 
restrictions during the COVID-19 pandemic. Most 
respondents were male, which reflects the population 
of forest goers and those at highest risk for malaria, 
and were ethnically diverse, drawn from a range of 
villages. The findings from interviews with trial par-
ticipants which may have been from a biased group of 
forest goers who were willing to participate in a clini-
cal trial and received intensive education and support 
introducing potential lack of external validity. This 
made it difficult to separate out views specifically 
about prophylaxis from views about participating 
in the clinical trial. The participants were therefore 
supplemented by interviews with those ineligible to 
join the trial, the number of which was very low. The 
framework developed by Sekhon and colleagues [31] 
was useful in exploring the multi-faceted nature of 
acceptability, it was however difficult to distinguish 
opportunity costs from burden of the intervention 
and they were hence merged in the findings.
Table 3 Main implications for implementation of malaria prophylaxis among forest goers
Main policy implications
Prophylaxis as a part of malaria intervention Prophylaxis should be implemented in combination with existing malaria services including use of ITNs, 
distribution of forest packages, and prompt testing and treatment
Targeting forest goers should consider their travel patterns and seasonality to ensure coverage of and 
access to the intervention, particularly among mobile population groups
Choice of regimen Choice of regimen needs to consider frequency, dosing, and especially potential side effects of the drug 
to encourage uptake and minimize non‑adherence
Delivery of prophylaxis and provider Delivery of prophylaxis should be from a local, trusted, and trained provider with support from an 
equipped healthcare facility
Prophylaxis should be prescribed with a package of high‑fat food (a pack of biscuits was used in this trial) 
to maximize lumefantrine absorption; the package should be easily portable and convenient for travelling 
and consumption in forest settings where meal preparation may be difficult
Messages about prophylaxis Messages about prophylaxis should be clear and comprehensible (verbally and/or visually) in local 
language(s) with considerations for illiterate individuals and ethnic groups
Information about the cause of malaria infection, how prophylaxis works as a prevention, and why some 
malaria patients are asymptomatic can create a better understanding of prophylaxis and encourage its 
uptake
Emphasize the importance of continuing other modes of prevention to protect from mosquito bites (i.e. 
use of other measures) together with prophylaxis (i.e. preventive medicine)
Convey that side effects are rare and mild, and short‑lived for those who may experience them
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Conclusion
The acceptability of anti-malarial chemoprophylaxis 
among forest goers in northern Cambodia is contingent 
on awareness of and concern about malaria, trust in the 
provider, and how prophylaxis is explained and deliv-
ered. The findings highlight how uptake and adherence 
to prophylaxis are influenced by the balance between 
perceived benefits and burden of anti-malarials, par-
ticularly their effectiveness and side effects, and the 
seasonality of forest visits and its influence on malaria 
risk. Implementing prophylaxis needs to consider how 
the preventive medication could be incorporated into 
an existing package of interventions of vector-control 
measures and malaria testing and treatment services; 
engaging multi-level stakeholders; and strengthening 
VMW’s capacity. The next step in the roll-out of for-
est goer malaria prophylaxis should be to explore how 
local health workers perform in managing prophylaxis 
outside of a clinical trial, and work out how best to tar-
get and scale up prophylaxis in the region.
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